KT-621
Atopic Dermatitis; Other Type 2/Allergic Diseases
Phase 1bActive
Key Facts
Indication
Atopic Dermatitis; Other Type 2/Allergic Diseases
Phase
Phase 1b
Status
Active
Company
About Kymera Therapeutics
Kymera Therapeutics is a leader in the targeted protein degradation field, translating its innovative Pegasus™ platform into a robust clinical pipeline. The company has achieved significant validation through positive early clinical data for its lead programs, KT-621 and KT-333, demonstrating proof-of-concept for its oral degraders. Kymera's strategy is to build a fully integrated biopharmaceutical company by advancing its wholly-owned assets while selectively leveraging strategic partnerships to expand its reach and capabilities.
View full company profile